Document is current
Any future updates will be listed below
-
Authors
Daniilidou, Makrina https://orcid.org/0000-0002-5460-9802
Holleman, Jasper
Hagman, Göran
Kåreholt, Ingemar
Aspö, Malin
Brinkmalm, Ann
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Solomon, Alina
Kivipelto, Miia
Sindi, Shireen
Matton, Anna
- License Information
-
More Information
Article History
Received: 21 August 2023
Revised: 23 August 2024
Accepted: 27 August 2024
First Online: 9 September 2024
Competing interests
: HZ has served at scientific advisory boards and/or as a consultant for AbbVie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). MK has served at scientific advisory boards at Biogen, Roche, Combinostics and Swedish Care International and given lectures in symposia sponsored by Biogen, Roche, Nutricia, Lundbeck, and Nestlé. All other authors reported no biomedical financial interests or potential conflicts of interest.
: The research conducted was approved by the Ethical Review Board in Sweden (ethical permits: 2020-06484 and 2014/524-31/1) and is in concordance with the 1964 Helsinki Declaration. All participants provided their written informed consent for this study.
